Show simple item record

dc.contributor.authorMottet, N
dc.contributor.authorClarke, Noel W
dc.contributor.authorDe Santis, M
dc.contributor.authorZattoni, F
dc.contributor.authorMorote, J
dc.contributor.authorJoniau, S
dc.date.accessioned2015-04-16T15:14:22Zen
dc.date.available2015-04-16T15:14:22Zen
dc.date.issued2015-03en
dc.identifier.citationImplementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed? 2015, 115 (3):364-72 BJU Inten
dc.identifier.issn1464-410Xen
dc.identifier.pmid24628790en
dc.identifier.doi10.1111/bju.12736en
dc.identifier.urihttp://hdl.handle.net/10541/550238en
dc.description.abstractMen receiving androgen-deprivation therapy will in time develop metastatic castrate-resistant prostate cancer (mCRPC). Whilst effective treatment options for mCRPC have traditionally been limited, new agents are becoming available. Since 2010, the number and class of agents available to treat mCRPC has increased dramatically. As such, there is a need for clear guidance on the optimum treatment and sequence of treatments for mCRPC before and after chemotherapy. This evidence-based statement, reflecting the views of the authors, provides suggestions on the continued relevance of conventional approaches to first- and second-line treatment in mCRPC, the potential role of novel treatments, and factors that may influence the choice of hormonal agents and/or chemotherapy.
dc.language.isoenen
dc.rightsArchived with thanks to BJU internationalen
dc.titleImplementing newer agents for the management of castrate-resistant prostate cancer: what is known and what is needed?en
dc.typeArticleen
dc.contributor.departmentUniversity Hospital, Saint Etienne, Franceen
dc.identifier.journalBJU Internationalen
html.description.abstractMen receiving androgen-deprivation therapy will in time develop metastatic castrate-resistant prostate cancer (mCRPC). Whilst effective treatment options for mCRPC have traditionally been limited, new agents are becoming available. Since 2010, the number and class of agents available to treat mCRPC has increased dramatically. As such, there is a need for clear guidance on the optimum treatment and sequence of treatments for mCRPC before and after chemotherapy. This evidence-based statement, reflecting the views of the authors, provides suggestions on the continued relevance of conventional approaches to first- and second-line treatment in mCRPC, the potential role of novel treatments, and factors that may influence the choice of hormonal agents and/or chemotherapy.


This item appears in the following Collection(s)

Show simple item record